



**SONIC  
HEALTHCARE  
LIMITED**

19 February 2026

The Manager – Listings  
Australian Securities Exchange Limited  
Exchange Centre  
20 Bridge Street  
SYDNEY NSW 2000

*Via electronic lodgement*

Dear Sir / Madam

**CEO PRESENTATION – HALF YEAR RESULTS TO 31 DECEMBER 2025**

At 10:00am AEST today, Dr Jim Newcombe, Chief Executive Officer, will host a presentation of Sonic Healthcare's results for the half year ended 31 December 2025. The slides for the presentation are enclosed.

The release of this announcement was authorised by the Board of Sonic Healthcare Limited.

Yours faithfully  
**Sonic Healthcare Limited**

**Paul Alexander**  
Company Secretary

ersonal use only

# Financial and Operational Review

Half-year ended 31 December 2025



**SONIC  
HEALTHCARE**

**Dr Jim Newcombe**

CEO, Sonic Healthcare

19 February 2026



# Forward-looking Statements

This presentation may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts and unexpected growth in costs and expenses.

The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Sonic Healthcare).

In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements. The information provided in this presentation is based on and should be read in conjunction with the Appendix 4D released to the ASX on 19 February 2026 and may include earnings figures restated on a 'constant currency' basis.



# Headlines

| A\$M<br>(Statutory)            | H1 FY 2026 | H1 FY 2025 | Change |
|--------------------------------|------------|------------|--------|
| Revenue                        | 5,445      | 4,669      | 17%    |
| EBITDA                         | 907        | 827        | 10%    |
| Net profit                     | 262        | 237        | 11%    |
| Cash generated from operations | 682        | 620        | 10%    |
| Earnings per share (A\$ cents) | 53.1       | 49.2       | 8%     |

- On track to achieve full-year earnings guidance
- Strong revenue growth including organic growth of 5%
- EPS improving and remains a top priority, along with return on invested capital
- Operating leverage and synergy realisation demonstrated by EBITDA margin enhancement for majority of the business
- Ongoing focus on cost control across the business
- Operating review of US business underway including rationalisation of anatomical pathology operations
- Capital management initiatives progressing



# FY 2026 Guidance Maintained

## **EBITDA guidance maintained (issued August 2025; reaffirmed November)**

- EBITDA A\$1.87 – A\$1.95 billion (constant currency)

## **Other guidance**

- Depreciation expense (including on leased assets) forecast to be A\$770 - \$780 million (constant currency) – reduced from previous guidance
- Interest expense to increase by ~15% (constant currency) versus prior year – tightened from previous guidance
- Effective tax rate ~27%

## **Key guidance considerations**

- Excludes any gains from sale of properties
- Includes completed acquisitions only
- No regulatory changes assumed
- Assumes current interest rates prevail



# Adjusted EBITDA Margins

|                                     | H1 FY 2026   | H1 FY 2025   | Margin Change |
|-------------------------------------|--------------|--------------|---------------|
| <b>Reported EBITDA margins</b>      | <b>16.7%</b> | <b>17.7%</b> |               |
| Acquisition costs                   | 0.2%         | 0.1%         |               |
| German KV quota change              | 0.3%         | -            |               |
| LADR acquisition                    | 0.2%         | -            |               |
| Hertfordshire & West Essex contract | 0.1%         | -            |               |
| USA                                 | 0.6%         | -            |               |
| <b>Adjusted EBITDA margins</b>      | <b>18.1%</b> | <b>17.8%</b> | <b>30 bps</b> |


- Operating leverage and synergy realisation demonstrated by EBITDA margin enhancement for majority of the business
- Acquisition costs: H1 FY 2026 A\$8 million; H1 FY 2025 A\$2 million
- German KV fee quota minimum level change took effect from 1 January 2025
- LADR acquisition settled 1 July 2025, lower initial margin than Sonic's average, as expected
- HWE contract margin improving but still dilutive, as expected
- USA margin decline due to low organic revenue growth and restructuring costs; less impact on group margin expected in H2 FY 2026





# Capital Management Priorities

- Maintain investment grade balance sheet
- Maintain progressive dividend with medium-term target dividend payout ratio of 70-80% of net profit
- Selective synergistic acquisitions
- Share buy-backs using surplus capital (e.g. sale and leaseback and/or other property sales)



# Dividend and Credit Metrics

Interim dividend

**\$0.45**

▲ 2.3% vs FY 2025

- Progressive dividend maintained
- Interim dividend 60% franked
- Record Date 5 March 2026
- Payment Date 19 March 2026

| Credit Metrics            |      | 31 December 2025 | 30 June 2025 |
|---------------------------|------|------------------|--------------|
| Net interest-bearing debt | A\$M | 3,600            | 2,818        |
| Equity                    | A\$M | 8,723            | 8,473        |
| Debt cover                | X    | 2.5              | 2.1          |
| Gearing ratio             | %    | 29.0             | 24.7         |
| Interest cover            | X    | 9.5              | 10.1         |

- Increase in net debt relates to acquisitions of LADR and Cairo Diagnostics
- Current available headroom ~A\$1 billion (before interim dividend)

- Debt cover = Net debt / EBITDA (covenant limit <3.5)
- Gearing ratio = Net debt / Net debt + equity (covenant limit <55%)
- Interest cover = EBITA / Net interest expense (covenant limit >3.25)
- Formulas as per facility definitions, which exclude impacts of AASB 16





# Capital Management Initiatives

## Sale and leaseback transactions

- Process underway for sale and leaseback of Brisbane hub laboratory
  - Estimated sale proceeds A\$450 – A\$500 million
  - Targeting June 2026 completion
  - Expect significant gain on sale, with potential tax capital gain partially sheltered by past capital losses (not on balance sheet)
- Further property sale and leaseback transactions under consideration (with potential gains on sale)



## Sale of surplus property


- Conditional heads of agreement in place to sell a surplus Australian property, settlement expected in FY 2027

## Share buy-back

- Opportunity to use part proceeds from property transactions to fund on-market share buy-back



# H1 FY 2026 Revenue



- Diverse global portfolio of medical practices
- Leading positions in stable and growing markets
- Attractive growth opportunities in existing markets


Total Revenue A\$5,445 million (including A\$8 million interest)

SCS / Other = Sonic Clinical Services (IPN Medical Centres, Sonic HealthPlus, other clinical service entities) and other minor operations

\* Switzerland revenue includes revenue from Liechtenstein



# Germany



## Revenue


- Growth 52% (statutory), 40% (constant currency)
- Organic growth 5% (constant currency)
- Organic growth impacted by change to minimum KV quota for statutory insurance fee (EBM) schedule, effective 1 January 2025, ~1% revenue impact as expected

## Operations

- LADR laboratory group acquisition settled 1 July 2025; integration across 16 separate workstreams well advanced and proceeding to plan, including first laboratory merger completed (in Berlin)
- Cycle of large-scale laboratory infrastructure investments complete with new Bremen national reference laboratory go-live planned for April 2026, following Biovis, Hamburg, and Munich laboratory projects and mergers
- Combination of strong organic growth, synergy capture and strict cost control driving margin expansion
- Successful diversification into high-value, medically led direct-to-consumer testing through dedicated brand, leveraging existing national infrastructure
- Proposed reform of GOA private fee schedule: no certainty reform will proceed, nor its potential timing or impact



# Australian Pathology



## Revenue


- Organic growth 5%

## Operations

- Annual indexation 2.4% from 1 July 2025 on ~30% of Medicare fees
- Ongoing implementation of private billing for selected tests
- Strong growth in specialist and hospital segments, with commencement of services at Hollywood Private Hospital in Perth from February 2026
- Acquisition and commencement of fitout of new hub laboratory in Melbourne to consolidate four facilities and create capacity for future growth
- Major laboratory platform procurement process completed, delivering substantial savings
- Awaiting final determination from Fair Work Commission Gender Undervaluation review; industry association in good faith discussions with Department of Health, Disability and Ageing on offsetting funding



# USA



## Revenue


- Growth 3% (statutory)
- Organic growth 0% (constant currency); underlying organic growth 2% (adjusted for Alabama major payor contract loss and restructuring of anatomical pathology operations)

## Operations

- Operating review with multiple improvement initiatives underway across all US operations
- Rationalisation of 9 AP practices, improving profitability, completing FY 2026
- Wind down of Alabama operations completed
- Enhanced revenue collection system delivering benefits but slower and likely less than previously expected
- Expanded advanced diagnostics division combining Cairo Diagnostics, ThyroSeq® and other highly specialised testing, maturing to nationwide product offering
- Ongoing digital pathology rollout supporting optimisation of workload distribution and productivity; >60% of dermatopathology volume currently on PathologyWatch platform
- PAMA fee cuts deferred, lobbying for permanent solution continues



# Switzerland



## Revenue


- Growth 12% (statutory)
- Organic growth 2% (constant currency)

## Operations

- Synergy realisation proceeding to plan with margin expansion achieved following acquisitions of Synlab Suisse (July 2023) and Dr. Risch group (March 2024)
- Laboratory mergers completed in Geneva, Lausanne, Zurich and Ticino
- Two largest mergers scheduled for hub laboratories in Berne (H2 FY 2026) and Lucerne (FY 2027), including upgrades to laboratory infrastructure and automation
- Continued strength in specialist and hospital segments, including new hospital contract win in Zurich (commencing January 2026)
- Harmonised core IT platforms (LIS, ERP), instrument standardisation and logistics network laying foundation for further integration and ongoing organic growth



# UK



## Revenue

- Growth 30% (statutory)
- Organic growth 24% (constant currency)


## Operations

- Hertfordshire and West Essex (HWE) NHS outsource contract commenced March 2025, integration proceeding to plan
- New hub lab in Watford expected to go live July 2026, servicing the HWE contract and creating capacity for further growth
- New pathology contracts
  - Royal National Orthopaedic Hospital service commenced November 2025, term 11 years
  - Large private specialist outpatient group from October 2025
  - Continuing to bid for additional private sector and NHS contracts
- Acquisition of Cellular Pathology Services completed November 2025 - accelerating growth in private anatomical pathology market





# Radiology



## Revenue and earnings


- Organic revenue growth 7%
- EBITDA growth 5% (normalised for IT cost reallocation – refer Appendix 4D)

## Operations

- Annual Medicare fee indexation 2.4% from 1 July 2025
- Ongoing focus on higher value modalities (CT, MRI, PET CT)
- Seven greenfield sites opened in FY 2025 and three in FY 2026 (one in H1), initially margin dilutive
- 23 existing MRIs fully licenced from July 2025 following change in Medicare licencing
- National Lung Cancer Screening program adding to CT revenue growth from July 2025
- Continued investments in AI and systems driving productivity gains



# Sonic Clinical Services



## Revenue and earnings

- Revenue growth 5% (organic growth flat)
- EBITDA growth 20%, off low base and including acquisition of National Skin Cancer Clinics (NSCC)

## Operations

- NSCC (acquired April 2025) now integrated with existing skin business and performing well
- Increased Medicare funding from November 2025 benefiting revenue and consultation numbers in general practice
- Range of cost management initiatives underway, including site rationalisations and realisation of operational synergies



# Sonic Healthcare's Value Proposition



# Thank you.



SONIC  
HEALTHCARE

